about
Managing bile acid diarrhoeaCoeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signallingRecent advances in the understanding of bile acid malabsorptionDefining primary bile acid diarrhea: making the diagnosis and recognizing the disorder.Human ileal bile acid-binding protein promoter and the effects of CDX2.The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer.Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.Cell and molecular biology of the small intestine: new insights into differentiation, growth and repair.Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal painTaurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+- and Cl(-)-dependent TauT (SLC6A6)Short bowel syndrome: the role of GLP-2 on improving outcome.New insights into bile acid malabsorption.Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.Recycling rate of bile acids in the enterohepatic recirculation as a major determinant of whole body 75SeHCAT retention.Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.The role of bile acids in functional GI disorders.The Farnesoid X Receptor: Good for BAD.A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolismFibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea.Analysis of the absolute risks in coeliac disease indicates the importance of the prevention of osteoporosis.Bile acids are physiological ligands for a nuclear receptor.New 2010 British Society of Gastroenterology colitis surveillance guidelines: costs and surveillance intervals.Differences in inflammatory bowel disease phenotype between South Asians and Northern Europeans living in North West London, UK.Duodenal expression of the epithelial calcium transporter gene TRPV6: is there evidence for Vitamin D-dependence in humans?A Twist in the Tale of a Pig Model of Short-Bowel Syndrome.Editorial: diagnosing bile acid diarrhoea with blood tests.Editorial: developing a stimulation test to identify FGF19 deficiency in bile acid diarrhoea.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.A common CTLA4 haplotype associated with coeliac diseaseAdequacy of flexible sigmoidoscopy with biopsy for diarrhea in patients under age 50 without features of proximal diseaseLetter: hydroxypropyl cellulose as therapy for chronic diarrhoea in patients with bile acid malabsorption - possible mechanismsEditorial: colesevelam effects on faecal bile acids in IBS with diarrhoeaLetter: long-term treatment of severe bile acid diarrhoea-obeticholic acid can normalise SeHCAT retentionNon-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational studyInhibition of luciferase expression from a commercial reporter vector by 1,25-dihydroxycholecalciferol.Plasma membrane calcium pump expression in human placenta and small intestineLichen planus associated with chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolutionIntestinal basolateral membrane Ca-ATPase activity with properties distinct from those of the Ca-pump
P50
Q24629001-F8DD1675-0C5A-4621-A946-725CD7A0E7A4Q28236179-2081FC3F-429C-4F41-BBBF-466BE1F4B67DQ28264279-E6CCC945-4533-4B5D-92B7-A420B3BA97A4Q34142506-6CD30258-E168-433F-89DC-EEE083519248Q34280815-605A9FF4-0DDD-45D0-83FD-87CEA22DC9A8Q34444158-E4A49EDB-8680-4F08-9A28-11C7BF3FBD0AQ34565684-21599F62-17BD-436C-B137-0E7793C8D710Q34990107-D92651BF-6374-4C18-BD72-ECE6FD30274FQ36036420-C2225039-50BE-45AD-950B-DB0C76E7619BQ36930795-DB1C9ADC-4203-44BD-96B1-1DDDCFB950EBQ37160620-5B70599B-0B9B-4565-9A00-6C44E0F7E2A9Q37498171-6F772A76-AAD5-40DD-84BA-D7E2513AE4BCQ37909078-C9AAA32F-4630-49E9-8238-665880897A7FQ38069608-A70DE168-304B-42C2-AD5E-A21D7EC78B5EQ38112366-0B68CEBB-9B95-4020-9379-1EB62138188CQ38198859-027C5D6C-A0FE-4682-913F-017E5C4DC1B8Q38217671-13E63F9C-5517-4FAA-A371-B41C44CFD554Q39125255-A476037A-464C-48FD-BDB5-7BCB5FFD0FE7Q40858310-2AC750EE-9B37-4788-B383-CD89EA365A88Q42263341-18677548-FAB9-46BD-A346-BCCA4FE4DFA9Q42843310-C615F60A-AC8D-4844-A876-1FD4549809B8Q43086567-18601138-6A71-4E81-A3B1-6635D5368B72Q43921897-4426BDB9-7A83-4FE7-B651-1341B56948CEQ43985967-63C0F1DE-3C0D-4D82-9D8C-ACA06CB16C0FQ44958248-A40654FB-35A4-4000-A71A-D534C6986564Q47095712-2833393E-9195-427C-B4C0-55B66A464C97Q48112817-4E382739-3C04-438B-B705-095D4A04C5E3Q48315900-37D95A1D-A8B8-48D4-902D-AAE828E6349BQ50535134-A767263F-9502-4533-85DE-24C3B3BBA243Q50687545-629AA8DD-F87B-4F34-A074-C78D2543F8FDQ56902893-8B2CBB50-F676-4981-8F33-FB178547EED5Q57121858-CFC5A74E-89E4-41DF-96AC-C7401A2FA580Q57134680-52F320C1-BCD4-4482-8490-C210BCD78FD1Q57145549-2528E777-D296-4BB8-8169-48D630114DBCQ57455147-2D1E6A89-217F-4D4D-BB1C-4DCD0F07E823Q61809688-82E37A62-635E-4928-81EC-05E719116288Q64925917-BCD71709-8BE8-4221-8D01-70C50C1A6355Q67486900-F85EA835-F5D9-47A7-99D9-29ABAEF0D2A7Q68078879-5162BDA2-29F0-4CC9-8FA2-FAD42ED5AEA6Q68984802-5E31101D-74D2-481A-8FD3-EF8418731D44
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
J R Walters
@ast
J R Walters
@en
J R Walters
@es
J R Walters
@nl
type
label
J R Walters
@ast
J R Walters
@en
J R Walters
@es
J R Walters
@nl
prefLabel
J R Walters
@ast
J R Walters
@en
J R Walters
@es
J R Walters
@nl
P31
P496
0000-0001-9720-5835